ECSP088306A - Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr - Google Patents

Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr

Info

Publication number
ECSP088306A
ECSP088306A EC2008008306A ECSP088306A ECSP088306A EC SP088306 A ECSP088306 A EC SP088306A EC 2008008306 A EC2008008306 A EC 2008008306A EC SP088306 A ECSP088306 A EC SP088306A EC SP088306 A ECSP088306 A EC SP088306A
Authority
EC
Ecuador
Prior art keywords
treat
ryr
formula
prevent
receivers
Prior art date
Application number
EC2008008306A
Other languages
English (en)
Inventor
Andrew Robert Marks
Donald W Landry
Shixian Deng
Zhen Zhuang Cheng
Stephan E Lehnart
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of ECSP088306A publication Critical patent/ECSP088306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La presente invención suministra compuestos de la Fórmula I: y sus sales, hidratos, solvatos, complejos y prodrogas. La presente invención suministra además métodos para sintetizar los compuestos de la Fórmula I. La invención suministra adicionalmente composiciones farmacéuticas que comprenden los compuestos de la fórmula I y métodos para usar las composiciones farmacéuticas de la Fórmula I para tratar y prevenir trastornos y enfermedades asociados con los receptores RyR que regulan el canal de calcio que funciona en las células.
EC2008008306A 2005-08-25 2008-03-24 Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr ECSP088306A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/212,413 US7704990B2 (en) 2005-08-25 2005-08-25 Agents for preventing and treating disorders involving modulation of the RyR receptors

Publications (1)

Publication Number Publication Date
ECSP088306A true ECSP088306A (es) 2008-07-30

Family

ID=37772221

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008306A ECSP088306A (es) 2005-08-25 2008-03-24 Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr

Country Status (34)

Country Link
US (1) US7704990B2 (es)
EP (4) EP2764867A1 (es)
JP (1) JP5342877B2 (es)
KR (2) KR101456342B1 (es)
CN (2) CN102558093B (es)
AP (1) AP3091A (es)
AR (1) AR057776A1 (es)
AU (1) AU2006283534C1 (es)
BR (1) BRPI0615097B1 (es)
CA (1) CA2620183C (es)
CR (1) CR9812A (es)
CY (3) CY1113974T1 (es)
DK (3) DK1928850T3 (es)
EA (1) EA014941B1 (es)
EC (1) ECSP088306A (es)
ES (3) ES2405780T3 (es)
GE (1) GEP20105134B (es)
HN (1) HN2008000299A (es)
HR (3) HRP20130669T1 (es)
IL (1) IL189675A (es)
MA (1) MA29785B1 (es)
MY (1) MY144622A (es)
NO (1) NO20081421L (es)
NZ (1) NZ566822A (es)
PL (3) PL1928850T3 (es)
PT (3) PT2177224E (es)
RS (3) RS52781B (es)
SI (3) SI2177224T1 (es)
SV (1) SV2008002828A (es)
TN (1) TNSN08078A1 (es)
TW (1) TWI486338B (es)
UA (1) UA93388C2 (es)
WO (1) WO2007024717A2 (es)
ZA (1) ZA200802338B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US8022058B2 (en) * 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) * 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008144483A2 (en) * 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
PT2250159E (pt) * 2008-03-03 2012-01-16 Servier Lab Processo para preparar benzotiazepinas a partir de gama aminoalquilbenzenos
AU2008243144A1 (en) * 2008-11-06 2010-05-20 Quark Technologies Australia Pty Ltd Improvements in Radiopharmaceutical Purification
AU2010219044B2 (en) * 2009-02-25 2012-10-04 Noboru Kaneko 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same
US8933129B2 (en) 2009-04-15 2015-01-13 State Of Oregon By And Through The State Board Of Higher Education On Behalf Of Portland State University Compounds and methods for modulating activity of calcium release channels
CN101812523B (zh) * 2010-04-09 2012-08-22 广州益善生物技术有限公司 Ryr1基因snp检测特异性引物、液相芯片和检测方法
WO2012019076A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
US9464322B2 (en) 2011-09-09 2016-10-11 University Of Kentucky Research Foundation Methods for diagnosing and treating alzheimer's disease (AD) using the molecules that stabilize intracellular calcium (Ca2+) release
EP2708535A1 (en) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
WO2016168694A1 (en) * 2015-04-15 2016-10-20 Ohio State Innovation Foundation Engineered calmodulin for treatment of ryanopathies
ES2643856B1 (es) * 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
MX2018015452A (es) 2016-12-15 2020-02-10 Soc Des Produits Nestle S A Star Composiciones y metodos que modulan fosforo o las enzimas en un aminal de compañia.
WO2019010386A1 (en) * 2017-07-06 2019-01-10 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF CATECHOLAMINERGIC POLYMORPH VENTRICULAR TACHYCARDIA RELATED DISORDERS
CN108588085B (zh) * 2018-05-30 2021-11-09 上海市第十人民医院 恶性心律失常的筛查试剂盒、动物模型的建立方法及应用
US11129871B1 (en) 2018-06-19 2021-09-28 Washington University Compositions and methods for treating and preventing endoplasmic reticulum (ER) stress-mediated kidney diseases
JP7595011B2 (ja) * 2019-07-22 2024-12-05 株式会社アエタスファルマ 光学活性な１，４－ベンゾチアゼピン－１－オキシド誘導体の製造方法
EP4247778A4 (en) * 2020-11-17 2025-03-05 RyCarma Therapeutics, Inc. Agents for treating disorders involving ryanodine receptors
AU2022205964A1 (en) 2021-01-08 2023-08-17 Rycarma Therapeutics, Inc. Crystalline forms of a ryanodine receptor modulator and uses thereof
US11717526B2 (en) 2021-05-20 2023-08-08 Armgo Pharma, Inc. Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
EP4548971A1 (en) * 2023-11-06 2025-05-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin 1,4-benzothiazepines and related compounds with cyclopropanol groups as multi-targeted drugs
CN119632990B (zh) * 2024-12-13 2025-11-18 温州医科大学 腔肠素在制备治疗心脏有关疾病的药物中的应用
CN119977904A (zh) * 2025-02-18 2025-05-13 合肥工业大学 一种苯并氧（碳/硫）氮杂䓬类化合物及其在医学上的应用

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
US3519647A (en) 1966-10-12 1970-07-07 Squibb & Sons Inc 2,3,4,5-tetrahydro-1,5-benzothiazepines
EP0150996B1 (en) 1984-01-27 1988-01-07 Ajinomoto Co., Inc. Manufacture of heptanoic acid derivatives
US4567254A (en) 1984-09-19 1986-01-28 Kikkoman Corporation Method for preparing N6,8-disubstituted 3',5'-cyclic adenosine monophosphate and salt thereof
US4849535A (en) 1985-02-26 1989-07-18 Ajinomoto Co., Inc. Production of cyclopentenylheptanoic acid derivatives
US4723012A (en) 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US4841055A (en) 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
DE3677201D1 (de) 1986-03-27 1991-02-28 Topy Ind Oxidationskatalysator fuer kohlenmonoxyd.
US6956032B1 (en) 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
JPS63227599A (ja) 1987-03-14 1988-09-21 Kirin Brewery Co Ltd アンスラサイクリン化合物およびその用途
US5210266A (en) 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
US5179125A (en) 1987-12-03 1993-01-12 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
EP0368063B1 (de) 1988-11-05 1992-06-10 Bayer Ag Verfahren zur Kernchlorierung von aromatischen Kohlenwasserstoffen
US5223508A (en) 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
US5272164A (en) 1988-12-27 1993-12-21 Kirin Beer Kabushiki Kaisha Carboximidamide derivatives
JPH0662567B2 (ja) 1988-12-27 1994-08-17 麒麟麦酒株式会社 ピリジンカルボキシイミダミド誘導体、その製造中間体、製造法および用途
US5142647A (en) 1989-04-18 1992-08-25 Japan Tobacco, Inc. Magnus measuring apparatus
CA1341094C (en) * 1989-09-25 2000-09-05 Ronald G. Worton Diagnosis for malignant hyperthermia
ES2084706T3 (es) 1989-09-30 1996-05-16 Kirin Brewery Metodo de produccion de plantones.
US5153184A (en) 1989-10-10 1992-10-06 Dowelanco ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
US5075293A (en) 1989-10-10 1991-12-24 The Dow Chemical Company ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
KR940000166B1 (ko) 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
US4963671A (en) 1989-11-20 1990-10-16 E. R. Squibb & Sons, Inc. Process for resolving chiral intermediates used in making calcium channel blockers
EP0460239A4 (en) 1989-12-27 1992-05-06 Japan Tobacco Inc. 1,3,2-dioxathiolane oxide derivative
KR920701200A (ko) 1990-03-30 1992-08-11 미즈노 시게루 신규의 4h-3,1-벤조옥사진-4-온 유도체
KR930700494A (ko) 1990-04-10 1993-03-15 시게루 미즈노 신규한 옥사디논 유도체
JP2651043B2 (ja) 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
US5082847A (en) 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility
US5064810A (en) 1990-09-14 1991-11-12 Jeffrey Askanazi Use of branched chain amino acids to effect diaphragm contractility and fatigue
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5180720A (en) 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5182272A (en) 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
CA2090677C (en) 1991-07-04 1996-08-27 Yoshihiro Watanabe Method for culturing t lineage precursor cells
CA2120939A1 (en) 1991-10-11 1993-04-15 Tetsuya Tahara Therapeutic agent for osteoporosis and diazepine compound
WO1993013082A1 (en) 1991-12-20 1993-07-08 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin e2 antagonists
MX9300433A (es) 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
JP2667351B2 (ja) 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
US5387684A (en) 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
JP3093419B2 (ja) 1992-03-30 2000-10-03 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
US5304644A (en) 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
KR950702188A (ko) 1992-07-02 1995-06-19 후지야마 로오 아미노산 유도체 생산 및 합성의 신규 중간체
CA2142883A1 (en) 1992-08-21 1994-03-03 Saizo Shibata Dioxacycloalkane compound having renin-inhibitory activity
US5260286A (en) 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
ATE163927T1 (de) 1992-11-09 1998-03-15 Knoll Ag 1,4-benzothiazepine verwendbar als neurologische mittel
US5354758A (en) 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
ZA94284B (en) * 1993-01-27 1994-08-17 Shionogi & Co Process for preparing benzothiazepine derivatives
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
ATE176237T1 (de) 1993-04-15 1999-02-15 Kirin Brewery Sphingoglycolipid und verwendung davon
US5354747A (en) 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5461047A (en) 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5824862A (en) 1993-08-19 1998-10-20 Japan Tobacco Inc. DNA encoding ATP-dependent fructose 6-phosphate 1-phosphotransferase originating from plant, recombinant vector containing the same and method for changing sugar content in plant cells under low temperature
FR2709753B1 (fr) 1993-09-09 1995-12-01 Hoechst Lab Nitrates organiques, leur procédé de préparation et leur application comme médicaments.
US5719155A (en) 1993-11-10 1998-02-17 Japan Tobacco Inc. Chroman derivative and pharmaceutical use thereof
US6897295B1 (en) 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5449675A (en) 1994-06-09 1995-09-12 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use
AU2682495A (en) 1994-06-15 1996-01-05 Kirin Beer Kabushiki Kaisha Novel transferase and amylase, process for producing the enzymes,use thereof, and gene coding for the same
US20040175814A1 (en) 1994-06-15 2004-09-09 Kirin Beer Kubushiki Kaisha Novel transferase and amylase, process for producing the enzymes, use thereof, and gene coding for the same
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
WO1996015152A1 (en) 1994-11-11 1996-05-23 International Reagents Corporation Antiannexin-v monoclonal antibody, process for producing the same, and use therof
EP0792880A4 (en) 1994-11-18 1998-03-25 Japan Tobacco Inc OSTEOPOROSIS MEDICINE AND TRIAZEPINE COMPOUND
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP3193301B2 (ja) 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US6660837B1 (en) 1995-09-14 2003-12-09 Kirin Beer Kabushiki Kaisha Modified protein derived from protein kinase N
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
ES2364179T3 (es) 1996-07-08 2011-08-26 Kyowa Hakko Kirin Co., Ltd. Compuestos con actividad receptora de calcio.
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
US6111072A (en) 1996-08-26 2000-08-29 Kirin Beer Kabushiki Kaisha Rho target protein human mDia and gene encoding same
ES2235259T3 (es) 1996-12-12 2005-07-01 Kirin Beer Kabushiki Kaisha Beta-1-4 n-acetilglucosaminiltransferasa y gen que la codifica.
TW555562B (en) 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6011036A (en) 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
DE19722317C1 (de) 1997-05-28 1998-10-08 Boehringer Ingelheim Int Das Protein des humanen Ryanodinrezeptors vom Typ 3 sowie dafür kodierende DNA-Moleküle
AUPO941497A0 (en) 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
CA2274776C (en) 1997-10-08 2008-11-25 Noboru Kaneko Method for analyzing annexin v in urine and use thereof
GB9724813D0 (en) 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
EP1043335A4 (en) 1997-12-25 2005-08-31 Japan Tobacco Inc MONOCLONAL ANTIBODY AGAINST THE BIND WEIGHT GROWTH FACTOR AND ITS MEDICAL USES
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6051714A (en) 1998-03-12 2000-04-18 Reilly Industries, Inc. Processes for dechlorinating pyridines
HUP0101275A3 (en) 1998-03-26 2002-12-28 Japan Tobacco Inc Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
HUP0101137A3 (en) 1998-04-10 2003-03-28 Japan Tobacco Inc Anticoagulant amidines and their pharmaceutical use
CA2318806A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding agents that modulate the 5-ht transporter
WO2000006724A1 (en) 1998-07-31 2000-02-10 Kirin Beer Kabushiki Kaisha Remedies for neuropathy containing as the active ingredient galectin-1 or its derivatives
CA2342602A1 (en) 1998-09-17 2000-03-30 Nippon Kayaku Kabushiki Kaisha Remedies for photochemotherapy
EP1147772B1 (en) 1998-12-28 2006-01-04 Noboru Kaneko Use of 1,4-benzothiazepine derivatives for the preparation of a medicament FOR the TREATMENT OF ATRIAL FIBRILLATION
DK1167537T3 (da) 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
WO2000071132A1 (en) 1999-05-19 2000-11-30 Japan Tobacco Inc Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
WO2001016321A1 (en) 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
ATE359788T1 (de) 1999-09-30 2007-05-15 Noboru Kaneko Verwendung von diphenylmethylpiperazin-derivaten zur herstellung eines medikaments zur unterdrückung der proliferation von fibroblasten
US7135466B2 (en) 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
EP1244457B1 (en) 1999-12-29 2004-10-27 Glaxo Group Limited Use of modulators of annexin for the manufacture of a medicament for the treatment and/or prevention of arthritis and arthritic diseases
ATE291737T1 (de) 2000-01-14 2005-04-15 Migenix Corp Screening-assays unter verwendung von intramitochondrialem kalzium
ATE362926T1 (de) 2000-01-20 2007-06-15 Eisai R&D Man Co Ltd Stickstoffhaltige cyclische verbindungen und sie enthaltende pharmazeutische zubereitungen
KR20020067937A (ko) * 2000-01-26 2002-08-24 오노 야꾸힝 고교 가부시키가이샤 벤젠 축합 헤테로환 유도체 및 그 유도체를 유효성분으로서 함유하는 약제
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
TWI288136B (en) 2000-02-18 2007-10-11 Kirin Brewery Novel isoxazole and thiazole compounds and use thereof as drugs
CN1294117C (zh) 2000-03-24 2007-01-10 法马西亚公司 用作一氧化氮合酶抑制剂的脒基化合物及其盐
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
US6545170B2 (en) 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
US6489125B1 (en) 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
AU2001261434A1 (en) 2000-05-11 2001-11-26 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
CN101498731A (zh) 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
EP1300142A4 (en) 2000-07-05 2004-05-19 Ajinomoto Kk HYPOGLYCEMIC COMPOUNDS
AU2001267879A1 (en) 2000-07-05 2002-01-14 Ajinomoto Co., Inc. Acylsulfonamide derivatives
CA2415826A1 (en) 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
WO2002010139A1 (en) 2000-08-01 2002-02-07 Pharmacia Corporation Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase
AR031608A1 (es) 2000-09-15 2003-09-24 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
TWI290130B (en) 2000-09-15 2007-11-21 Pharmacia Corp 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
US6936426B2 (en) 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
US6673904B2 (en) 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
US6962926B2 (en) 2001-01-31 2005-11-08 Telik, Inc. Antagonist of MCP-1 function, and compositions and methods of use thereof
JPWO2002061076A1 (ja) 2001-02-01 2004-06-03 持田製薬株式会社 アディポネクチン関連蛋白質
JP4817514B2 (ja) 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
WO2002072145A1 (en) 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedies for depression containing ep1 antagonist as the active ingredient
US20030054531A1 (en) 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
WO2002078625A2 (en) 2001-03-28 2002-10-10 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
TWI324154B (es) 2001-04-27 2010-05-01 Kyowa Hakko Kirin Co Ltd
JP4230681B2 (ja) 2001-07-06 2009-02-25 株式会社東芝 高耐圧半導体装置
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
NZ531917A (en) 2001-09-14 2006-01-27 Japan Tobacco Inc Linked biaryl compounds
JP2003095977A (ja) * 2001-09-21 2003-04-03 Masafumi Yano 筋肉収縮・弛緩機能障害関連疾患の治療又は予防剤
WO2003041495A1 (en) 2001-11-15 2003-05-22 Kirin Beer Kabushiki Kaisha Chimeric nonhuman animal
JP2003145746A (ja) 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
JPWO2003043655A1 (ja) 2001-11-19 2005-03-10 小野薬品工業株式会社 頻尿の治療剤
EP1452530A4 (en) 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
WO2003061699A1 (en) 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
US20040171613A1 (en) 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
CA2471639A1 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
TWI262917B (en) 2002-02-01 2006-10-01 Dainippon Sumitomo Pharma Co 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
ATE522207T1 (de) 2002-02-14 2011-09-15 Kirin Brewery Zusammensetzungen und nahrungsmittel zur verbesserung des fettstoffwechsels
CN1655696A (zh) 2002-04-26 2005-08-17 日本烟草产业株式会社 棒状物品成形装置
CA2483518A1 (en) 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
JP4113042B2 (ja) 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
JP2004103256A (ja) 2002-09-04 2004-04-02 Nippon Chemicon Corp 非常灯
US7615564B2 (en) 2002-09-12 2009-11-10 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
EP1541153A1 (en) 2002-09-20 2005-06-15 Kirin Beer Kabushiki Kaisha Hepatitis c virus inhibitor comprising alpha-glycosylceramide as the active ingredient
CN1717483A (zh) 2002-10-04 2006-01-04 麒麟麦酒株式会社 人类人工染色体(hac)载体
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2003301894A1 (en) 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
EP1439221B1 (en) 2002-12-17 2007-01-24 F. Hoffmann-La Roche Ag PDE core construct
PE20050194A1 (es) 2003-02-13 2005-04-23 Banyu Pharma Co Ltd Derivados de piridina-2-carboxamida como activadores de glucoquinasa
TWI220798B (en) 2003-03-07 2004-09-01 Hitachi Cable Light-emitting diode array
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
KR20050110017A (ko) 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
MXPA05009848A (es) 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
CL2004000544A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
EP1614676A4 (en) 2003-03-27 2009-03-25 Kirin Pharma Kk CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF
TW200500362A (en) 2003-04-09 2005-01-01 Japan Tobacco Inc 5-membered heteroaromatic ring compound and pharmaceutical use thereof
US20040229803A1 (en) 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20050159403A1 (en) 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
US20060135506A1 (en) 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20050009733A1 (en) 2003-04-22 2005-01-13 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
TWI494102B (zh) 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20050070543A1 (en) 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
EP1653969A4 (en) 2003-08-07 2006-12-20 Japan Tobacco Inc PYRROLO 1,2-B PYRIDAZINE DERIVATIVES
CA2536173A1 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20070238740A1 (en) 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
US20050187221A1 (en) 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
JP2007515490A (ja) 2003-12-22 2007-06-14 アムジェン インコーポレーティッド アリールスルホンアミド化合物およびそれに関連する使用法
US7165879B2 (en) 2004-03-25 2007-01-23 Red Devil Equipment Company Clamp lock apparatus and method for a paint mixer
CA2563064A1 (en) 2004-04-22 2005-11-10 Kirin Beer Kabushiki Kaisha Transgenic animals and uses thereof
WO2005105793A1 (ja) 2004-04-28 2005-11-10 Aetas Pharma Co., Ltd. 筋弛緩促進剤及び筋弛緩不全等の筋組織に係る疾病の治療薬
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
BRPI0513286A (pt) 2004-07-15 2008-05-06 Japan Tobacco Inc compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos
JP2006094849A (ja) 2004-08-30 2006-04-13 Kirin Brewery Co Ltd 相同組換え効率が向上した分化多能性細胞及びその利用
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7396829B2 (en) 2005-02-24 2008-07-08 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
WO2006098394A1 (ja) 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
HRP20130360T1 (hr) 2013-06-30
ES2405765T3 (es) 2013-06-03
JP2009506034A (ja) 2009-02-12
AU2006283534A1 (en) 2007-03-01
CN101500576A (zh) 2009-08-05
IL189675A (en) 2013-12-31
SI2177224T1 (sl) 2013-06-28
SI2311464T1 (sl) 2013-06-28
RS52852B (sr) 2013-12-31
NZ566822A (en) 2011-04-29
AU2006283534C1 (en) 2012-08-02
MY144622A (en) 2011-10-14
TNSN08078A1 (en) 2009-07-14
CN102558093A (zh) 2012-07-11
KR20080037741A (ko) 2008-04-30
HK1137150A1 (en) 2010-07-23
CY1113975T1 (el) 2016-07-27
CR9812A (es) 2009-09-14
CN102558093B (zh) 2014-10-15
JP5342877B2 (ja) 2013-11-13
ZA200802338B (en) 2009-01-28
RS52780B (sr) 2013-10-31
WO2007024717A2 (en) 2007-03-01
EP1928850A4 (en) 2009-06-17
HK1153664A1 (en) 2012-04-05
PT1928850E (pt) 2013-08-23
TWI486338B (zh) 2015-06-01
DK2311464T3 (da) 2013-05-13
AR057776A1 (es) 2007-12-19
MA29785B1 (fr) 2008-09-01
PL2311464T3 (pl) 2013-07-31
EP2311464A1 (en) 2011-04-20
KR101456342B1 (ko) 2014-11-03
DK1928850T3 (da) 2013-09-23
RS52781B (sr) 2013-10-31
HRP20130669T1 (hr) 2013-08-31
PL1928850T3 (pl) 2013-11-29
PL2177224T3 (pl) 2013-07-31
AP3091A (en) 2015-01-31
EP1928850A2 (en) 2008-06-11
SI1928850T1 (sl) 2013-09-30
CY1114091T1 (el) 2016-07-27
HRP20130353T1 (hr) 2013-06-30
KR20120025626A (ko) 2012-03-15
EP2177224A2 (en) 2010-04-21
PT2311464E (pt) 2013-05-15
UA93388C2 (uk) 2011-02-10
BRPI0615097A2 (pt) 2009-07-14
EP2764867A1 (en) 2014-08-13
GEP20105134B (en) 2010-12-27
IL189675A0 (en) 2008-06-05
EP2177224A3 (en) 2010-06-30
DK2177224T3 (da) 2013-05-13
ES2405780T3 (es) 2013-06-03
NO20081421L (no) 2008-05-23
BRPI0615097B1 (pt) 2021-06-01
EP2177224B1 (en) 2013-02-27
HK1119705A1 (en) 2009-03-13
SV2008002828A (es) 2010-07-20
CA2620183A1 (en) 2007-03-01
EP2311464B1 (en) 2013-02-13
EA200800665A1 (ru) 2008-08-29
PT2177224E (pt) 2013-05-15
CA2620183C (en) 2014-04-15
CY1113974T1 (el) 2016-07-27
US20070049572A1 (en) 2007-03-01
HN2008000299A (es) 2011-07-11
TW200800930A (en) 2008-01-01
US7704990B2 (en) 2010-04-27
EA014941B1 (ru) 2011-04-29
WO2007024717A3 (en) 2009-01-08
EP1928850B1 (en) 2013-06-19
ES2421159T3 (es) 2013-08-29
CN101500576B (zh) 2013-08-14
AU2006283534B2 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
MX2012000256A (es) Compuestos terapeuticos y composiciones.
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
PA8570701A1 (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparacion
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
CO6311051A2 (es) Compuestos de pirimidina, composiciones y metodos de uso
ECSP077270A (es) Ácidos de tiazolo - naftilo
CR11229A (es) Pirimidil ciclopentanos como inhibidores de proteina cinasa akt
UY28215A1 (es) Quinazolinas utiles como moduladores de canales iónicos
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CR10600A (es) Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa
CR8753A (es) Derivados de tetraazabenzo [e] azuleno y sus analogos
CR10601A (es) Ciclopenta (d) pirimidinas como inhibidores de la proteina cinasa akt
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
UY31065A1 (es) Heterociclos ciclicos
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
DOP2009000242A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
GT200600117A (es) Nuevos compuestos farmaceuticos
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos